ANTIVIRAL DRUGS ADVISORY COMMITTEE
(Discuss the Use of Surrogate Markers in the Early Development of Immunomodulatory Agents for the Treatment of Patients with Human Immunodeficiency Virus (HIV))

October 16, 2000

Slides

Need for New Therapies, Lawrence Fox, MD, PhD   ppt   html

An Overview of Candidate Immunologic Biomarkers and Surrogate Markers, Alan Landay, PhD   ppt   html

Surrogate Markers as Measures of Efficacy:  Limitations & Complexities, Thomas R Fleming PhD  pdf

CDER Meeting: Surrogate Markers of Immunity, Judith A Britz, PhD  ppt   html

The Role of Glutathione in Cell Defense, with References to Clinical Deficiencies and Treatment, Thomas A Kwyer, MD  ppt   html